Abstract

Transgenic mouse models of Alzheimer's disease (AD) with abundant β-amyloid develop memory impairments. However, multiple nonmnemonic cognitive domains such as attention and executive control are also compromised early in AD individuals, but have not been routinely assessed in animal models. Here, we assessed the cognitive abilities of TgCRND8 mice—a widely used model of β-amyloid pathology—with a touch screen-based automated test battery. The test battery comprises highly translatable tests of multiple cognitive constructs impaired in human AD, such as memory, attention, and response control, as well as appropriate control tasks. We found that familial AD mutations affect not only memory, but also cause significant alterations of sustained attention and behavioral flexibility. Because changes in attention and response inhibition may affect performance on tests of other cognitive abilities including memory, our findings have important consequences for the assessment of disease mechanisms and therapeutics in animal models of AD. A more comprehensive phenotyping with specialized, multicomponent cognitive test batteries for mice might significantly advance translation from preclinical mouse studies to the clinic.

Highlights

  • Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that is characterized by an accelerated decline of cognitive abilities

  • To ensure a comparable level of disease progression, testing was performed with 3 cohorts: cohort 1 was used for the object recognition task, cohort 2 was tested on visual discrimination, reversal, and extinction, and cohort 3 was tested on the 5-choice serial reaction time task (5-CSRTT), which was immediately followed by the extinction paradigm

  • Because manual scoring of exploration is notoriously sensitive to experimenter bias, we have developed an automated, touch screen-based version of the object recognition paradigm, where animals explore 2-dimensional images of objects displayed on the touch screen

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that is characterized by an accelerated decline of cognitive abilities. Because plaques of aggregated ␤-amyloid (A␤) peptide and tangles of hyperphosphorylated tau protein are prominent anatomical hallmarks in the brains of AD patients (Braak and Braak, 1991, 1995), the discovery of mutations in genes encoding these peptides in familial AD patients promised to be a major breakthrough for the understanding of the disease. C. Romberg et al / Neurobiology of Aging 34 (2013) 731–744.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call